Abstract
Both short-term and long-term effects of the β-sympathomimetic drugs isoprenaline and terbutaline on the urinary excretion of histamine and its two main metabolites were evaluated in patients with systemic mastocytosis.
In a short-term study isoprenaline and terbutaline were given intravenously during five hours to three and two patients, respectively. Compared with placebo infusion Nt-methyl-histamine excretion fell during terbutaline administration, whereas during isoprenaline no changes were observed.
In a long-term study three patients received a treatment with orally administered terbutaline for 24 days. In one patient a slight reduction of the excretion of the histamine metabolites was found. In another patient the excretion of histamine and its metabolites, decreased especially during the eight days observation period after the end of the treatment. In this study we saw occasionally large and rapid changes occurring simultaneously in all three urinary parameters of histamine release.
In conclusion, terbutaline can reduce histamine release in systemic mastocytosis. However, because of the small symptomatic and biochemical effects found in our patients, the clinical significance of β-sympathomimetic drug treatment in this disease has yet to be established.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
M. Frieri, D.W. Alling andD.D. Metcalfe,Comparison of the therapeutic efficacy, of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis. Results of a double-blind clinical trial, Amer. J. Med.78, 9–14 (1985).
N.A. Soter, K.F. Austen andS.I. Wasserman,Oral disodium cromoglycate in the treatment of systemic mastocytosis, N. Engl. J. Med.301, 465–469 (1979).
J.G.R. de Monchy, J.J. van Doormaal, S. Janssen, H. Doorenbos andJ.J. Keyzer,Effect of oral, inhaled and intravenous disodium cromoglycate on histamine production in patients with systemic mastocytosis, Frontiers in histamine research, an international symposium Jouy-en-Josas, near Paris (France) 25–27 July 1984, Abstract 51.
G. Granerus, J. Olafsson andG. Roupe,Treatment of two mastocytosis patients with a histidine decarboxylase inhibitor, Agents and Actions16, 244–248 (1985).
P.E. Alm andG.D. Bloom,Catecholamine inhibition of rat mast cell histamine secretion — a process independent of cyclic amp levels and counteracted by glucose, Life Sci.32, 307–314 (1983).
D.S. Postma, G.H. Koëter, J.J. Keyzer andH. Meurs,Influence of slow release terbutaline on the circadian variation of catecholamines, histamine, and lung function in non-allergic patients with partly reversible airflow obstruction, J. Allergy Clin. Immunol. In press.
G.H. Koëter, D.S. Postma, J.J. Keyzer andH. Meurs,Effect of oral slow-release terbutaline on early morning dyspnoea, Eur. J. Clin. Pharmacol.28, 159–162 (1985).
J.J. Keyzer, J.G.R. de Monchy, J.J. van Doormaal andP.C. van Voorst Vader,Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites, N. Engl. J. Med.309, 1603–1605 (1983).
J. Turk, J.A. Oates andL.J. Jackson II,Intervention with epinephrine in hypotension associated with mastocytosis, J. Allergy Clin. Immunol.71, 189–192 (1983).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van Doormaal, J.J., Idema, I.G., de Monchy, J.G.R. et al. Effects of isoprenaline and terbutaline on urinary excretion of histamine and its two main metabolites in systemic mastocytosis. Agents and Actions 18, 269–272 (1986). https://doi.org/10.1007/BF01988039
Issue Date:
DOI: https://doi.org/10.1007/BF01988039